Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Return on Sales (2016 - 2025)

Historic Return on Sales for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to 0.33%.

  • Cytosorbents' Return on Sales fell 100.0% to 0.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.44%, marking a year-over-year increase of 1100.0%. This contributed to the annual value of 0.58% for FY2024, which is 3600.0% up from last year.
  • Cytosorbents' Return on Sales amounted to 0.33% in Q3 2025, which was down 100.0% from 0.44% recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Return on Sales registered a high of 0.08% during Q4 2022, and its lowest value of 1.5% during Q3 2022.
  • Over the past 5 years, Cytosorbents' median Return on Sales value was 0.66% (recorded in 2021), while the average stood at 0.67%.
  • The largest annual percentage gain for Cytosorbents' Return on Sales in the last 5 years was 7800bps (2022), contrasted with its biggest fall of -8900bps (2022).
  • Over the past 5 years, Cytosorbents' Return on Sales (Quarter) stood at 0.86% in 2021, then skyrocketed by 91bps to 0.08% in 2022, then tumbled by -830bps to 0.76% in 2023, then dropped by -9bps to 0.83% in 2024, then skyrocketed by 60bps to 0.33% in 2025.
  • Its last three reported values are 0.33% in Q3 2025, 0.44% for Q2 2025, and 0.17% during Q1 2025.